Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant human nerve growth factor injection for acute non-arteritic anterior ischemic optic neuropathy
CTR20232035Phase 2Completed
- Sponsor
- Beijing Institute of Biotechnology
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of cenegermin in non-arteritic anterior ischemic optic neuropathy (NAION), Optic neuropathies, sponsored by Beijing Institute of Biotechnology. Started Jan 2024; status: completed.
02
Drugs
cenegermin
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)Optic neuropathies
Beyond the preview
Go deeper on CTR20232035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232035.